Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study
Clinical and Translational Science · 2026-04 · 19 (4)
DOI: 10.1111/cts.70481 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 29.03.2026. Verfasst von Jixiang Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Clinical Trials Center, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Cytidine, Hydroxylamines. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation. An open‐label, fixed‐sequence, Phase 1 study was conducted to evaluate the tolerability, safety, and pharmacokinetics (PK) following single and multiple (every 12 h for 5.5 days) oral dosing of molnupiravir 800 mg in 16 healthy, male Chinese participants. After multiple doses of molnupiravir, the median time to maximum concentration was 2.0 h for plasma NHC. NHC concentrations generally decreased in a biphasic manner, with a terminal half‐life of 21.9 h, and NHC exposures (i.e., area under the curve and maximum plasma concentration) were similar following single and multiple doses of molnupiravir. No accumulation of NHC in plasma was observed. When compared with historical data from published clinical trials of similar study design, NHC exposure in Chinese participants was marginally higher than that in non‐Asian participants but remained within established clinical bounds. Overall, molnupiravir was generally well‐tolerated. Ten participants (63.5%) experienced at least one adverse event throughout the study, the severity of which was mild or moderate, and none led to treatment discontinuation. There were no clinically meaningful findings in other safety evaluations. These data support use of the standard 5‐day regimen of molnupiravir 800 mg every 12 h without dose adjustment for the treatment of COVID‐19 in the Chinese population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Clinical Trials Center, Peking University Third Hospital, Beijing, China.
- MSD China, Beijing, China.
- MSD China, Shanghai, China.
- Merck & Co., Inc., Rahway, New Jersey, USA.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
- Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Fang Sun, Brian M Maas, Mickie H Cheng, S Aubrey Stoch, Haiyan Li
Zitieren
APA
Zhu, J., Zhang, D., Liu, Z., Yan, B., Zang, Y., Zhao, W., Sun, F., Maas, B. M., Cheng, M. H., Stoch, S. A., & Li, H. (2026). Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study. Clinical and Translational Science, 19(4). https://doi.org/10.1111/cts.70481
Vancouver
Zhu J, Zhang D, Liu Z, Yan B, Zang Y, Zhao W, et al. Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study. Clinical and Translational Science. 2026;19(4). doi:10.1111/cts.70481
BibTeX
@article{Zhu2026,
author = {Zhu, Jixiang and Zhang, Danning and Liu, Zhiping and Yan, Bei and Zang, Yanqiao and Zhao, Weiwei and Sun, Fang and Maas, Brian M and Cheng, Mickie H and Stoch, S Aubrey and Li, Haiyan},
title = {Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {4},
doi = {10.1111/cts.70481}
}
EUVIMED